Blue Jet Healthcare Limited’s board has approved a proposal to raise up to ₹1,000 crore through the issuance of equity shares or other eligible instruments, even as the company reported a sharp decline in earnings for the fourth quarter of FY26.
The fundraise may be executed through a qualified institutional placement, rights issue, or other permissible routes, subject to shareholder and regulatory approvals.
The capital raise announcement came alongside quarterly results that showed significant pressure on both revenue and profitability. Revenue from operations fell 31.1% year-on-year to ₹234.67 crore in Q4 FY26 from ₹340.45 crore in the same quarter last year. Net profit dropped 41.6% to ₹64.34 crore from ₹110.10 crore in Q4 FY25.
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹234.67 cr | ₹340.45 cr | -31.1% |
| Total Income | ₹257.59 cr | ₹352.67 cr | -26.9% |
| Profit Before Tax | ₹87.15 cr | ₹147.21 cr | -40.8% |
| Net Profit | ₹64.34 cr | ₹110.10 cr | -41.6% |
| Basic EPS (₹) | ₹3.71 | ₹6.35 | -41.6% |
For the full year FY26, revenue from operations stood at ₹947.32 crore against ₹1,029.99 crore in FY25, an 8% decline year-on-year. Full-year net profit came in at ₹247.82 crore, down 18.8% from ₹305.20 crore in FY25.
| Metric | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Revenue from Operations | ₹947.32 cr | ₹1,029.99 cr | -8.0% |
| Total Income | ₹1,015.98 cr | ₹1,076.24 cr | -5.6% |
| Profit Before Tax | ₹332.51 cr | ₹406.10 cr | -18.1% |
| Net Profit | ₹247.82 cr | ₹305.20 cr | -18.8% |
| Basic EPS (₹) | ₹14.29 | ₹17.59 | -18.8% |
Blue Jet Healthcare is a specialty pharmaceutical company focused on contrast media and other high-value active pharmaceutical ingredients. The proposed fundraise, if executed, would significantly bolster the company’s balance sheet at a time when earnings have come under pressure across both quarterly and annual horizons.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult a qualified financial advisor before making any investment decisions.